Product image of Lanreotidă Zentiva (Lanreotide) supplied by GNH India

Lanreotidă Zentiva

Active Ingredient:
Lanreotide
Origin:
EU

Lanreotidă Zentiva (Lanreotide)

Lanreotide, the active ingredient in Lanreotidă Zentiva, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed to manage hormone‑related disorders such as acromegaly and certain neuroendocrine tumors in adult patients.
GNH India supplies Lanreotidă Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lanreotidă Zentiva is a somatostatin analogue used in endocrine‑related disease pathways.

  • Acromegaly: reduces excess growth hormone secretion and helps normalize IGF‑1 levels.
  • Neuroendocrine tumors (carcinoid syndrome): controls hormone‑driven flushing and diarrhea.
  • Hormone‑secreting tumors: mitigates hypersecretion of various hormones, improving clinical symptoms.

How It Works

  • Lanreotide is a synthetic analogue of somatostatin that binds with high affinity to somatostatin receptor subtypes (SSTR2, SSTR5) on target cells. Receptor activation inhibits adenylate cyclase activity, reducing cyclic AMP levels and suppressing the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby modulating endocrine function.

Side Effects

Lanreotidă Zentiva may cause adverse reactions that vary in frequency and severity.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Nausea: transient feeling of queasiness.
  • Diarrhea: loose stools that may be mild to moderate.
  • Headache: occasional throbbing pain.
  • Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects

  • Gallbladder disease: formation of gallstones or cholecystitis.
  • Pancreatitis: inflammation of the pancreas requiring medical attention.
  • Severe allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Cardiac arrhythmias: irregular heart rhythms that may need monitoring.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications.

  • Glucose monitoring: check blood sugar regularly, especially in diabetic patients.
  • Gallbladder evaluation: assess for gallstones or biliary disease prior to treatment.
  • Cardiac assessment: review history of arrhythmias or conduction disorders.
  • Concomitant hormone therapies: adjust doses of insulin or oral hypoglycemics as needed.
  • Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide can interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

  • Other somatostatin analogues: additive hormonal suppression may increase adverse effects.
  • Insulin or oral hypoglycemics: heightened risk of hypoglycemia, requiring dose adjustment.
  • QT‑prolonging agents: potential for serious cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely)

  • CYP450 substrates: lanreotide may alter metabolism of certain drugs, affecting their plasma levels.
  • Antiplatelet or anticoagulant drugs: increased bleeding tendency may occur.
  • Diuretics: electrolyte imbalances could be exacerbated, necessitating periodic labs.

Frequently Asked Questions

Lanreotidă Zentiva is prescribed for adults with acromegaly, a disorder of excess growth hormone, and for patients with neuroendocrine tumors such as carcinoid syndrome, where it helps control hormone‑related symptoms like flushing and diarrhea.

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors on endocrine cells. This binding blocks the release of several hormones, including growth hormone, insulin, and glucagon, thereby reducing the hormonal excess that drives conditions like acromegaly and neuroendocrine tumor symptoms.

The specific dose and dosing interval of Lanreotidă Zentiva are determined by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. Patients should follow the individualized regimen provided by their healthcare professional.

Safety data for lanreotide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and a healthcare provider should be consulted.

To request Lanreotidă Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lanreotidă Zentiva, like other long‑acting somatostatin analogues (e.g., octreotide), provides sustained receptor activation with less frequent dosing. Its pharmacokinetic profile may allow monthly subcutaneous administration, offering convenience compared with shorter‑acting agents that require more frequent injections.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Lanreotidă Zentiva is given as a subcutaneous injection, typically by a healthcare professional. The injection site is rotated to minimize local irritation, and the medication is administered according to the schedule prescribed by the treating physician.

Serious adverse events include gallbladder disease (gallstones or cholecystitis), pancreatitis, severe allergic reactions such as anaphylaxis, and cardiac arrhythmias. Patients should be monitored for abdominal pain, jaundice, sudden swelling, or any signs of an allergic response and seek medical attention promptly.

Lanreotidă Zentiva is contraindicated in patients with known hypersensitivity to lanreotide or any of the excipients. Caution is advised for individuals with severe gallbladder disease, uncontrolled diabetes, or significant cardiac conduction abnormalities, and it should be avoided in pregnancy unless clearly justified.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT